SCHEMBL3227328

SCHEMBL3227328

OC[C@H]1OC(c2ncccn2)C[C@@H]1O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
CSNK2A3 Q8NEV1 1/20 0.39
ADRB1 P08588 1/20 0.39
DNMT1 P26358 1/20 0.39
MAPT P10636 1/20 0.37
CDA P32320 1/20 0.37
OGA O60502 2/20 0.36
GALR3 O60755 1/20 0.36
NR2F2 P24468 1/20 0.36
HIF1A Q16665 1/20 0.36
PDE4D Q08499 2/20 0.35
SLC5A2 P31639 1/20 0.35
PNP P00491 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HTT P42858 1/20 0.35
PDE3A Q14432 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10702398 1.00 PIM1 (0.39) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL15492630 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL12671725 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL1065647 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL14389130 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL2154637 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL20857297 0.74 PDE4D (0.44) MAPTGALR3NR2F2PDE4DSLC5A2
SCHEMBL10183373 0.73 CYP1A2 (0.38) GALR3NR2F2HIF1APDE4DSLC5A2
SCHEMBL7122115 0.73 MMP2 (0.40) PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL13705702 0.73 CYP1A2 (0.38) GALR3NR2F2HIF1APDE4DSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056468-A1 Pyrimidine Derivatives As Anticancer Agents UNIVERSITY HEALTH NETWORK (CA) 2010-03-04 US disclosed
WO-2008083465-A1 PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS UNIVERSITY HEALTH NETWORK (CA) 2008-07-17 WO disclosed
EP-0523110-A1 NUCLEOSIDE DERIVATIVES NYCOMED IMAGING AS (NO) 1993-01-20 EP disclosed
WO-1991015498-A2 NUCLEOSIDE DERIVATIVES NYCOMED IMAGING AS (NO) 1991-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056468-A1 Pyrimidine Derivatives As Anticancer Agents DPYD, TYMP, TYMS PIM1 2319/4885CSNK2A2 1820/4885CSNK2B 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.